LawGrids logoLAWGRIDS.ORG

The Drugs and Cosmetics Act, 1940

Dadra and Nagar Haveli and Daman and Diu Act - part 2 of 2

The text of this Act is shown as one document.

Full text

• Bilirubin • SGPT (ALT) T (AST) LDL Cholester (Non-r only) • SGO • atase (Non-rodents only) d Urea Nitrogen • Ceatinine Alkaline Phosph (ALP) • GGT • Bloo • Total Proteins • Albumin n lculated Sodium • Globuli (Ca values) • • • us Calcium Potassium Phosphor • Gross and Microscopic Pathology , • (Spinal Cord) • Eye • (Middle Ear) • Brain*: Cerebrum, cerebellum Midbrain • Thyroid • Parathyroid) • Spleen • Thymus • Adrenal* as) • (Pancre • (Trachea) • Lung* • Heart* • Aorta • Oesophagus ch • Stoma • Duodenum • Jejunum • • Colon Terminal ileum • (Rectum) • Liver* • Kidney* ladder • Urinary b • Epididymis • Testis* • Ovary • Uterus* • Skin • ary • mph node • Skeletal muscle Mamm gland ly Mesenteric * Organs marked with an asterisk should be weighed. () Organs listed in parenthesis should be examined if indicated by the nature of the drug or safety evaluation data of an IND needed for the conduct of _________________________________________________________________________ observed effects. Non-clinical toxicity testing and different phases of clinical trials. __ Drugs and Cosmetics Rules, 1945 531 Note: Refer Appendix III (Points 1.1 through 1.7 and tables 1.8 and 1.9) for essential features of study designs of the non-clinical toxicity studies listed below. For Phase I Clinical Trials Systemic Toxicity studies (i) Single dose toxicity studies (ii) Dose Ranging Studies (iii) Repeat-dose systemic toxicity studies of appropriate duration to support the duration of proposed human exposure. Male fertility study In-vitro genotoxicity tests Relevant local toxicity studies with proposed route of clinical application (duration depending on proposed length of clinical exposure) Allergenicity/Hypersensitivity tests (when there is a cause for concern or for parenteral drugs, including dermal application) Photo-allergy or dermal photo-toxicity test (if the drug or a metabolite is related to an agent causing photosensitivity or the nature of action suggests such a potential) For Phase II Clinical Trials Provide a summary of all the non-clinical safety data (listed above) already submitted while obtaining the permissions for Phase I trial, with appropriate references. In case of an application for directly starting a Phase II trial - complete details of the non- clinical safety data needed for obtaining the permission for Phase I trial, as per the list provided above must be submitted. Repeat-dose systemic toxicity studies of appropriate duration to support the duration of proposed human exposure In-vivo genotoxicity tests. Segment II reproductive/developmental toxicity study (if female patients of child bearing age are going to be involved) For Phase III Clinical Trials Provide a summary of all the non-clinical safety data (listed above) already submitted while obtaining the permissions for Phase I and II trials, with appropriate references. In case of an application for directly initiating a Phase III trial - complete details of the non-clinical safety data needed for obtaining the permissions for Phase I and II trials, as per the list provided above must be provided. Repeat-dose systemic toxicity studies of appropriate duration to support the duration of proposed human exposure Reproductive/developmental toxicity studies Segment I (if female patients of child bearing age are going to be involved), and Segment III (for drugs to be given to pregnant or nursing mothers or where there are indications of possible adverse effects on foetal development). Drugs and Cosmetics Rules, 1945 532 Carcinogenicity studies (when there is a cause for concern or when the drug is to be used for more than 6 months). For Phase IV Clinical Trials Provide a summary of all the non-clinical safety data (listed above) already submitted while obtaining the permissions for Phase I, II and III trials, with appropriate references. In case an application is made for initiating the Phase IV trial, complete details of the non-clinical safety data needed for obtaining the permissions for Phase I, II and III trials, as per the list provided above must be submitted. Application Of Good Laboratory Practices (GLP) The animal studies be conducted in an accredited laboratory. Where the safety pharmacology studies are part of toxicology studies, these studies should also be conducted in an accredited laboratory. APPENDIX IV ANIMAL PHARMACOLOGY 1. General Principles Specific and general pharmacological studies should be conducted to support use of therapeutics in humans. In the early stages of drug development enough information may not be available to rationally select study design for safety assessment. In such a situation, a general approach to safety pharmacology studies can be applied. Safety pharmacology studies are studies that investigate potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure within the therapeutic range or above. 1.1 Specific Pharmacological Actions Specific pharmacological actions are those which demonstrate the therapeutic potential for humans. The specific studies that should be conducted and their design will be different based on the individual properties and intended uses of investigational drug. Scientifically validated methods should be used. The use of new technologies and methodologies in accordance with sound scientific principles should be preferred. 1.2 General Pharmacological Actions 1.2.1 Essential Safety Pharmacology Safety pharmacology studies need to be conducted to investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure within the therapeutic range and above. These studies should be designed to identify undesirable pharmacodynamic properties of a substance that may have relevance to its human safety; to evaluate adverse pharmacodynamic and/or pathophysiological effects observed in toxicology and/or clinical studies; and to investigate the mechanism of the adverse pharmacodynamic effects observed and/or suspected. The aim of the essential safety pharmacology is to study the effects of the test drug on vital functions. Vital organ systems such as cardiovascular, respiratory and central nervous systems should be studied. Essential safety pharmacology studies may be excluded or supplemented based on scientific rationale. Also, the exclusion of certain Drugs and Cosmetics Rules, 1945 533 test(s) or exploration(s) of certain organs, systems or functions should be scientifically justified. 1.2.1.1 Cardiovascular System Effects of the investigational drug should be studied on blood pressure, heart rate, and the electrocardiogram. If possible in vitro, in vivo and/or ex vivo methods including electrophysiology should also be considered. 1.2.1.2 Central Nervous System Effects of the investigational drug should be studied on motor activity, behavioral changes, coordination, sensory and motor reflex responses and body temperature. 1.2.1.3 Respiratory System Effects of the investigational drug on respiratory rate and other functions such as tidal volume and hemoglobin oxygen saturation should be studied. 1.3 Follow-up and Supplemental Safety Pharmacology Studies In addition to the essential safety pharmacological studies, additional supplemental and follow-up safety pharmacology studies may need to be conducted as appropriate. These depend on the pharmacological properties or chemical class of the test substance, and the data generated from safety pharmacology studies, clinical trials, pharmacovigilance, experimental in vitro or in vivo studies, or from literature reports. 1.3.1 Follow-up Studies For Essential Safety Pharmacology Follow-up studies provide additional information or a better understanding than that provided by the essential safety pharmacology. 1.3.1.1 Cardiovascular System These include ventricular contractility, vascular resistance and the effects of chemical mediators, their agonists and antagonists on the cardiovascular system. 1.3.1.2 Central Nervous System These include behavioral studies , learning and memory, electrophysiology studies , neurochemistry and ligand binding studies. 1.3.1.3 Respiratory System These include airway resistance, compliance, pulmonary arterial pressure, blood gases and blood pH. 1.3.2 Supplemental Safety Pharmacology Studies These studies are required to investigate the possible adverse pharmacological effects that are not assessed in the essential safety pharmacological studies and are a cause for concern. 1.3.2.1 Urinary System These include urine volume, specific gravity, osmolality, pH, proteins, cytology and blood urea nitrogen, creatinine and plasma proteins estimation. 1.3.2.2 Autonomic Nervous System These include binding to receptors relevant for the autonomic nervous system, and functional response to agonist or antagonist responses in vivo or in vitro, and effects of direct stimulation of autonomic nerves and their effects on cardiovascular responses. Drugs and Cosmetics Rules, 1945 534 1.3.2.3 Gastrointestinal System These include studies on gastric secretion, gastric pH measurement, gastric mucosal examination, bile secretion, gastric emptying time in vivo and ileocaecal contraction in vitro. 1.3.2.4 Other Organ Systems Effects of the investigational drug on organ systems not investigated elsewhere should be assessed when there is a cause for concern. For example dependency potential, skeletal muscle, immune and endocrine functions may be investigated. 1.4 Conditions Under Which Safety Pharmacology Studies Are Not Necessary Safety pharmacology studies are usually not required for locally applied agents e.g. dermal or ocular, in cases when the pharmacology of the investigational drug is well known, and/or when systemic absorption from the site of application is low. Safety pharmacology testing is also not necessary, in the case of a new derivative having similar pharmacokinetics and pharmacodynamics. 1.5 Timing Of Safety Pharmacology Studies In Relation To Clinical Development 1.5.1 Prior To First Administration In Humans The effects of an investigational drug on the vital functions listed in the essential safety pharmacology should be studied prior to first administration in humans. Any follow-up or supplemental studies identified, should be conducted if necessary, based on a cause for concern. 1.5.2 During Clinical Development Additional investigations may be warranted to clarify observed or suspected adverse effects in animals and humans during clinical development 1.5.3 Before applying for marketing Approval Follow-up and supplemental safety pharmacology studies should be assessed prior to approval unless not required, in which case this should be justified. Available information from toxicology studies addressing safety pharmacology endpoints or information from clinical studies can replace such studies. 1.6 Application Of Good Laboratory Practices (GLP) The animal studies be conducted in an accredited laboratory. Where the safety pharmacology studies are part of toxicology studies, these studies should also be conducted in an accredited laboratory. APPENDIX V INFORMED CONSENT 1. Checklist for study Subject’s informed consent documents 1.1 Essential Elements: 1. Statement that the study involves research and explanation of the purpose of the research 2. Expected duration of the Subject's participation Drugs and Cosmetics Rules, 1945 535 3. Description of the procedures to be followed, including all invasive procedures and 4. Description of any reasonably foreseeable risks or discomforts to the Subject 5. Description of any benefits to the Subject or others reasonably expected from research. If no benefit is expected Subject should be made aware of this. 6. Disclosure of specific appropriate alternative procedures or therapies available to the Subject. 7. Statement describing the extent to which confidentiality of records identifying the Subject will be maintained and who will have access to Subject’s medical records 8. Trial treatment schedule(s) and the probability for random assignment to each treatment (for randomized trials) 9. Compensation and/or treatment(s) available to the Subject in the event of a trial- related injury 10. An explanation about whom to contact for trial related queries, rights of Subjects and in the event of any injury 11. The anticipated prorated payment, if any, to the Subject for participating in the trial 12. Subject's responsibilities on participation in the trial 13. Statement that participation is voluntary, that the subject can withdraw from the study at any time and that refusal to participate will not involve any penalty or loss of benefits to which the Subject is otherwise entitled 14. Any other pertinent information 1.2 Additional elements, which may be required (a) Statement of foreseeable circumstances under which the Subject's participation may be terminated by the Investigator without the Subject's consent. (b) Additional costs to the Subject that may result from participation in the study. (c) The consequences of a Subject’s decision to withdraw from the research and procedures for orderly termination of participation by Subject. (d) Statement that the Subject or Subject's representative will be notified in a timely manner if significant new findings develop during the course of the research which may affect the Subject's willingness to continue participation will be provided. (e). A statement that the particular treatment or procedure may involve risks to the Subject (or to the embryo or fetus, if the Subject is or may become pregnant), which are currently unforeseeable (f) Approximate number of Subjects enrolled in the study 2. Format of informed consent form for Subjects participating in a clinical trial Informed Consent form to participate in a clinical trial Study Title: Study Number: Drugs and Cosmetics Rules, 1945 536 Subject’s Initials: _______________ Subject’s Name:_______________ Date of Birth / Age: _________________ Please initial box (Subject) (i) I confirm that I have read and understood the information sheet dated ___ for the above study and have had the opportunity to ask questions. [ ] (ii) I understand that my participation in the study is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected. [ ] (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not need my permission to look at my health records both in respect of the current study and any further research that may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I understand that my identity will not be revealed in any information released to third parties or published. [ ] (iv) I agree not to restrict the use of any data or results that arise from this study provided such a use is only for scientific purpose(s) [ ] (v) I agree to take part in the above study. [ ] Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:_____________ Date: _____/_____/______ Signatory’s Name: ______________________________________________________ Signature of the Investigator: ____________________________ Date: _____/_____/______ Study Investigator’s Name: __________________________________________________ Drugs and Cosmetics Rules, 1945 537 Signature of the Witness ______________________ Date:_____/_____/_______ Name of the Witness: _______________________________________________________ APPENDIX VI FIXED DOSE COMBINATIONS (FDCs) Fixed Dose Combinations refer to products containing one or more active ingredients used for a particular indication(s). FDCs can be divided into the following groups and data required for approval for marketing is described below: (a) The first group of FDCs includes those in which one or more of the active ingredients is a new drug. For such FDCs to be approved for marketing data to be submitted will be similar to data required for any new drug (including clinical trials) [see rule 122E, item (a)]. (b)(i) The second group FDCs includes those in which active ingredients already approved/marketed individually are combined for the first time, for a particular claim and where the ingredients are likely to have significant interaction of a pharmacodynamic or pharmacokinetic nature [see rule 122E, item (c)]. If clinical trials have been carried out with the FDC in other countries, reports of such trials should be submitted. If the FDC is marketed abroad, the regulatory status in other countries should be stated. (see Appendix I, item 9). (ii) For marketing permission, appropriate chemical and pharmaceutical data will be submitted. In case such a combination is not marketed anywhere in the world but these drugs are already in use concomitantly (not as an FDC but individually) for the said claim, marketing permission may be granted based on chemical and pharmaceutical data. Data showing the stability of the proposed dosage form will also have to be submitted. (iii) For any other such FDCs, clinical trials may be required. For obtaining permission to carry out clinical trials with such FDCs a summary of available pharmacological, toxicological and clinical data on the individual ingredients should be submitted, along with the rationale for combining them in the proposed ratio. In addition, acute toxicity data (LD 50) and pharmacological data should be submitted on the individual ingredients as well as their combination in the proposed ratio. (c) The third group of FDCs includes those which are already marketed, but in which it is proposed either to change the ratio of active ingredients or to make a new therapeutic claim. For such FDCs, the appropriate rationale including published reports (if any) should be submitted to obtain marketing permission. Permission will be granted depending upon the nature of the claim and data submitted. (d) The fourth group of FDC includes those whose individual active ingredients (or drugs from the same class) have been widely used in a particular indication(s) for years, their concomitant use is often necessary and no claim is proposed to be made other than convenience. It will have to be demonstrated that the proposed dosage form is stable and the ingredients are unlikely to have significant interaction of a pharmacodynamic or pharmacokinetic nature. No additional animal or human data are generally required for these FDCs, and marketing permission may be granted if the FDC has an acceptable rationale. Drugs and Cosmetics Rules, 1945 538 APPENDIX VII UNDERTAKING BY THE INVESTIGATOR 1. Full name, address and title of the Principal Investigator (or Investigator(s) when there is no Principal Investigator) 2. Name and address of the medical college, hospital or other facility where the clinical trial will be conducted: Education, training & experience that qualify the Investigator for the clinical trial (Attach details including Medical Council registration number, and / or any other statement(s) of qualification(s)) 3. Name and address of all clinical laboratory facilities to be used in the study. 4. Name and address of the Ethics Committee that is responsible for approval and continuing review of the study. 5. Names of the other members of the research team (Co- or sub-Investigators) who will be assisting the Investigator in the conduct of the investigation (s). 6. Protocol Title and Study number (if any) of the clinical trial to be conducted by the Investigator. 7. Commitments: (i) I have reviewed the clinical protocol and agree that it contains all the necessary information to conduct the study. I will not begin the study until all necessary Ethics Committee and regulatory approvals have been obtained. (ii) I agree to conduct the study in accordance with the current protocol. I will not implement any deviation from or changes of the protocol without agreement by the Sponsor and prior review and documented approval / favorable opinion from the Ethics Committee of the amendment, except where necessary to eliminate an immediate hazard(s) to the trial Subjects or when the change(s) involved are only logistical or administrative in nature. (iii) I agree to personally conduct and/or supervise the clinical trial at my site. (iv) I agree to inform all Subjects, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent and ethics committee review and approval specified in the GCP guidelines are met. (v) I agree to report to the Sponsor all adverse experiences that occur in the course of the investigation(s) in accordance with the regulatory and GCP guidelines. (vi) I have read and understood the information in the Investigator's brochure, including the potential risks and side effects of the drug. (vii) I agree to ensure that all associates, colleagues and employees assisting in the conduct of the study are suitably qualified and experienced and they have been informed about their obligations in meeting their commitments in the trial. (viii) I agree to maintain adequate and accurate records and to make those records available for audit / inspection by the Sponsor, Ethics Committee, Licensing Authority or their authorized representatives, in accordance with regulatory and GCP provisions. I will fully cooperate with any study related audit conducted by regulatory officials or authorized representatives of the Sponsor. (ix) I agree to promptly report to the Ethics Committee all changes in the clinical trial activities and all unanticipated problems involving risks to human Subjects or others. Drugs and Cosmetics Rules, 1945 539 (x) I agree to inform all unexpected serious adverse events to the Sponsor as well as the Ethics Committee within seven days of their occurence. (xi) I will maintain confidentiality of the identification of all participating study patients and assure security and confidentiality of study data. (xii) I agree to comply with all other requirements, guidelines and statutory obligations as applicable to clinical Investigators participating in clinical trials 8. Signature of Investigator with Date APPENDIX VIII ETHICS COMMITTEE 1. The number of persons in an Ethcis Committee should have atleast seven members. Ethics Committee should appoint, from among its members, a Chairperson (who is from outside the institution) and a Member Secretary. Other members should be a mix of medical/non-medical, scientific and non-scientific persons, including lay public, to reflect the different viewpoints. For review of each protocol the quorum of Ethics Committee should be atleast 5 members with the following representations: (a) basic medical scientists (preferably one pharmacologist). (b) clinicians (c) legal expert (d) social scientist / representative of non-governmental voluntary agency / philosopher / ethicist / theologian or a similar person (e) lay person from the community. In any case, the ethics committee must include at least one member whose primary area of interest / specialization is nonscientific and at least one member who is independent of the institution / trial site. Besides, there should be appropriate gender representation on the Ethics Committee. If required, Subject experts may be invited to offer their views. Further, based on the requirement of research area, e.g. HIV AIDS, genetic disorders etc. specific patient groups may also be represented in the Ethics Committee as far as possible. Only those Ethics Committee members who are independent of the clinical trial and the Sponsor of the trial should vote / provide opinion in matters related to the study. 2. Format for Approval of Ethics Committee To Dr. Dear Dr. ________ The Institutional Ethics Committee / Independent Ethics Committee (state name of the committee, as appropriate) reviewed and discussed your application to conduct the clinical trial entitled “……” on …….(date). Drugs and Cosmetics Rules, 1945 540 The following documents were reviewed: (a) Trial Protocol (including protocol amendments), dated____________ Version no (s).__________ (b) Patient Information Sheet and Informed Consent Form (including updates if any) in English and/or vernacular language. (c) Investigator’s Brochure, dated_________, Version no.________ (d) Proposed methods for patient accrual including advertisement (s) etc. proposed to be used for the purpose. (e) Principal Investigator’s current CV. (f) Insurance Policy / Compensation for participation and for serious adverse events occurring during the study participation. (g) Investigator’s Agreement with the Sponsor. (h) Investigator’s Undertaking (Appendix VII). The following members of the ethics committee were present at the meeting held on (date, time, place). __________ Chairman of the Ethics Committee __________ Member secretary of the Ethics Committee __________ Name of each member with designation We approve the trial to be conducted in its presented form. The Institutional Ethics Committee / Independent Ethics Committee expects to be informed about the progress of the study, any SAE occurring in the course of the study, any changes in the protocol and patient information/informed consent and asks to be provided a copy of the final report. Yours sincerely, Member Secretary, Ethics Committee. APPENDIX IX STABILITY TESTING OF NEW DRUGS Stability testing is to be performed to provide evidence on how the quality of a drug substance or formulation varies with time under the influence of various environmental factors such as temperature, humidity and light, and to establish shelf life for the formulation and recommended storage conditions. Drugs and Cosmetics Rules, 1945 541 Stability studies should include testing of those attributes of the drug substance that are susceptible to change during storage and are likely to influence quality, safety, and/or efficacy. In case of formulations the testing should cover, as appropriate, the physical, chemical, biological, and microbiological attributes, preservative content (e.g., antioxidant, antimicrobial preservative), and functionality tests (e.g., for a dose delivery system). Validated stability-indicating analytical procedures should be applied. For long term studies, frequency of testing should be sufficient to establish the stability profile of the drug substance. In general, a drug substance should be evaluated under storage conditions that test its thermal stability and, if applicable, its sensitivity to moisture. The storage conditions and the length of studies chosen should be sufficient to cover storage, shipment and subsequent use. Stress testing of the drug substance should be conducted to identify the likely degradation products, which in turn establish the degradation pathways, evaluate the intrinsic stability of the molecule and validate the stability indicating power of the analytical procedures used. The nature of the stress testing will depend on the individual drug substance and the type of formulation involved. Stress testing may generally be carried out on a single batch of the drug substance. It should include the effect of temperatures ), humidity where appropriate, oxidation, and photolysis on the drug substance. Data should be provided for (a) Photostability on at least one primary batch of the drug substance as well as the formulation, as the case may be and (b) the susceptibility of the drug substance to hydrolysis across a wide range of pH values when in solution or suspension. Long-term testing should cover a minimum of 12 months’ duration on at least three primary batches of the drug substance or the formulation at the time of submission and should be continued for a period of time sufficient to cover the proposed shelf life. Accelerated testing should cover a minimum of 6 months duration at the time of submission. In case of drug substances, the batches should be manufactured to a minimum of pilot scale by the same synthetic route and using a method of manufacture that simulates the final process to be used for production batches. In case of formulations, two of the three batches should be at least pilot scale and the third one may be smaller. The manufacturing process(es) used for primary batches should simulate that to be applied to production batches and should provide products of the same quality and meeting the same specifications as that intended for marketing. The stability studies for drug substances should be conducted either in the same container - closure system as proposed for storage and distribution or in a container - closure system that simulates the proposed final packaging. In case of formulations, the stability studies should be conducted in the final container - closure system proposed for marketing. Stability Testing of new drug substances and formulations: (i) Study conditions for drug substances and formulations intended to be stored under general conditions Study Study conditions Duration of study Long term 30°C ± 2°C/65% RH ± 5% RH 12 months Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months Drugs and Cosmetics Rules, 1945 542 If at any time during 6 months’ testing under the accelerated storage condition, such changes occur that cause the product to fail in complying with the prescribed standards, additional testing under an intermediate storage condition should be conducted and evaluated against significant change criteria. (ii) Study conditions for drug substances and formulations intended to be stored in a refrigerator Study Study conditions Duration of study Long term 5°C ± 3°C 12 months Accelerated 25°C ± 2°C/60% RH ± 5% RH 6 months (iii) Study conditions for drug substances and formulations intended to be stored in a freezer Study Study conditions Duration of study Long term - 20°C ± 5°C 12 months (iv) Drug substances intended for storage below -20°C shall be treated on a case-by-case basis. (v) Stability testing of the formulation after constitution or dilution, if applicable, should be conducted to provide information for the labelling on the preparation, storage condition, and in-use period of the constituted or diluted product. This testing should be performed on the constituted or diluted product through the proposed in-use period. APPENDIX X CONTENTS OF THE PROPOSED PROTOCOL FOR CONDUCTING CLINICAL TRIALS 1. Title Page (a) Full title of the clinical study, (b) Protocol / Study number, and protocol version number with date (c) The IND name/number of the investigational drug (d) Complete name and address of the Sponsor and contract research organization if any (e) List of the Investigators who are conducting the study, their respective institutional affiliations and site locations (f) Name(s) of clinical laboratories and other departments and/or facilities participating in the study. 2. Table of Contents A complete Table of Contents including a list of all Appendices. Drugs and Cosmetics Rules, 1945 543 1. Background and Introduction (a) Preclinical experience. (b) Clinical experience. Previous clinical work with the new drug should be reviewed here and a description of how the current protocol extends existing data should be provided. If this is an entirely new indication, how this drug was considered for this should be discussed. Relevant information regarding pharmacological, toxicological and other biological properties of the drug/biologic/medical device, and previous efficacy and safety experience should be described. 2. Study Rationale This section should describe a brief summary of the background information relevant to the study design and protocol methodology. The reasons for performing this study in the particular population included by the protocol should be provided. 3. Study Objective(s) (primary as well as secondray) and their logical relation to the study design. 4. Study Design (a) Overview of the Study Design: Including a description of the type of study (i.e., double-blind, multicentre, placebo controlled, etc.), a detail of the specific treatment groups and number of study Subjects in each group and investigative site, Subject number assignment, and the type, sequence and duration of study periods. (b) Flow chart of the study (c) A brief description of the methods and procedures to be used during the study. (d) Discussion of Study Design: This discussion details the rationale for the design chosen for this study. 5. Study Population: the number of Subjects required to be enrolled in the study at the investigative site and by all sites along with a brief description of the nature of the Subject population required is also mentioned. 6. Subject Eligibility (a) Inclusion Criteria (b) Exclusion Criteria 7. Study Assessments – plan, procedures and methods to be described in detail 8. Study Conduct stating the types of study activities that would be included in this section would be: medical history, type of physical examination, blood or urine testing, electrocardiogram (ECG), diagnostic testing such as pulmonary function tests, symptom measurement, dispensation and retrieval of medication, Subject cohort assignment, adverse event review, etc. Each visit should be described separately as Visit 1, Visit 2, etc. Discontinued Subjects: Describes the circumstances for Subject withdrawal, dropouts, or other reasons for discontinuation of Subjects . State how dropouts would be managed and if they would be replaced Describe the method of handling of protocol waivers, if any. The person(s) who approves all such waivers should be identified and the criteria used for specific waivers should be provided. Drugs and Cosmetics Rules, 1945 544 Describes how protocol violations will be treated, including conditions where the study will be terminated for non-compliance with the protocol. 9. Study Treatment (a) Dosing schedule (dose, frequency, and duration of the experimental treatment) Describe the administration of placebos and/or dummy medications if they are part of the treatment plan. If applicable, concomitant drug(s), their doses, frequency, and duration of concomitant treatment should be stated. (b) Study drug supplies and administration: A statement about who is going to provide the study medication and that the investigational drug formulation has been manufactured following all regulations Details of the product stability, storage requirements and dispensing requirements should be provided. (c) Dose modification for study drug toxicity: Rules for changing the dose or stopping the study drug should be provided. (d) Possible drug interactions. (e) Concomitant therapy: The drugs that are permitted during the study and the conditions under which they may be used are detailed here. Describe the drugs that a Subject is not allowed to use during parts of or the entire study. If any washout periods for prohibited medications are needed prior to enrolment, these should be described here. (f) Blinding procedures: A detailed description of the blinding procedure if the study employs a blind on the Investigator and/or the Subject. (g) Unblinding procedures: If the study is blinded, the circumstances in which unblinding may be done and the mechanism to be used for unblinding should be given. 10. Adverse Events (See Appendix XI): Description of expected adverse events should be given. Procedures used to evaluate an adverse event should be described. 11`. Ethical Considerations: Give the summary of: (a) Risk/benefit assessment: (b) Ethics Committee review and communications. (c) Informed consent process. (d) Statement of Subject confidentiality including ownership of data and coding procedures. 12. Study Monitoring and Supervision: A description of study monitoring policies and procedures should be provided along with the proposed frequency of site monitoring visits, and who is expected to perform monitoring. Case Record Form (CRF) completion requirements, including who gets which copies of the forms and any specifics required in filling out the forms CRF correction requirements, including who is authorized to make corrections on the CRF and how queries about study data are handled and how errors, if any, are to be corrected should be stated. Investigator study files, including what needs to be stored following study completion should be described. 13. Investigational Product Management Drugs and Cosmetics Rules, 1945 545 (a) Give Investigational product description and packaging (stating all Ingredients and the formulation of the investigational drug and any placebos used in the study) (b) The precise dosing required during the study. (c) Method of packaging, labelling, and blinding of study substances. (d) Method of assigning treatments to Subjects and the Subject identification code numbering system. (e) Storage conditions for study substances. (f) Investigational product accountability: Describe instructions for the receipt, storage, dispensation, and return of the investigational products to ensure a complete accounting of all investigational products received, dispensed, and returned/destroyed. (g.)Describe policy and procedure for handling unused investigational products. 14. Data Analysis: Provide details of the statistical approach to be followed including sample size, how the sample size was determined, including assumptions made in making this determination, efficacy endpoints (primary as well as secondary) and safety endpoints. Statistical analysis: Give complete details of how the results will be analyzed and reported along with the description of statistical tests to be used to analyze the primary and secondary endpoints defined above. Describe the level of significance, statistical tests to be used, and the methods used for missing data; method of evaluation of the data for treatment failures, non-compliance, and Subject withdrawals; rationale and conditions for any interim analysis if planned. Describe statistical considerations for Pharmacokinetic (PK) analysis, if applicable. 15. Undertaking by the Investigator (see Appendix VII). 16. Appendices: Provide a study synopsis, copies of the informed consent documents (patient information sheet, informed consent form etc.); CRF and other data collection forms; a summary of relevant pre-clinical safety information and any other documents referenced in the clinical protocol. APPENDIX XI Data Elements for reporting serious adverse events occuring in a clinical trial 1. Patient Details Initials & other relevant identifier (hospital/OPD record number etc.)* Gender Age and/or date of birth Weight Height 2. Suspected Drug(s) Generic name of the drug*. Indication(s) for which suspect drug was prescribed or tested. Dosage form and strength. Drugs and Cosmetics Rules, 1945 546 Daily dose and regimen (specify units - e.g., mg, ml, mg/kg). Route of administration. Starting date and time of day. Stopping date and time, or duration of treatment 3. Other Treatment(s) Provide the same information for concomitant drugs (including non prescription/OTC drugs) and non-drug therapies, as for the suspected drug(s). 4. Details of Suspected Adverse Drug Reaction(s) Full description of reaction(s) including body site and severity, as well as the criterion (or criteria) for regarding the report as serious. In addition to a description of the reported signs and symptoms, whenever possible, describe a specific diagnosis for the reaction.* Start date (and time) of onset of reaction. Stop date (and time) or duration of reaction. Dechallenge and rechallenge information. Setting (e.g., hospital, out-patient clinic, home, nursing home). 5. Outcome Information on recovery and any sequelae; results of specific tests and/or treatment that may have been conducted. For a fatal outcome, cause of death and a comment on its possible relationship to the suspected reaction; any post-mortem findings. Other information: anything relevant to facilitate assessment of the case, such as medical history including allergy, drug or alcohol abuse; family history; findings from special investigations etc. 6. Details about the Investigator* Name Address Telephone number Profession (speciality) Date of reporting the event to Licensing Authority: Date of reporting the event to Ethics Committee overseeing the site: Signature of the Investigator Note: Information marked * must be provided.” Drugs and Cosmetics Rules, 1945 547 Records of amendments carried out Amendment list number and date Amendments carried out Initial of the person carrying out the amendments and date